Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.



In August 2011 crizotinib (Xalkori; Pfizer), a small-molecule kinase inhibitor, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer that is anaplastic lymphoma kinase-positive, as detected by an FDA-approved test.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Crizotinib.


  1. 1

    Janku, F. et al. Targeted therapy in non-small-cell lung cancer — is it becoming a reality? Nature Rev. Clin. Oncol. 7, 401–414 (2010).

    CAS  Article  Google Scholar 

  2. 2

    Soda, M. et al. Identification of the transforming EML4ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–567 (2007).

    CAS  Article  PubMed  Google Scholar 

  3. 3

    McDermott, U. et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 68, 3389–3395 (2008).

    CAS  Article  PubMed  Google Scholar 

  4. 4

    Zou, H. Y. et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408–4417 (2007).

    CAS  Article  PubMed  Google Scholar 

  5. 5

    Cui, J. J. et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition Factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54, 6342–6363 (2011).

    CAS  Article  PubMed  Google Scholar 

  6. 6

    US Food and Drug Administration. FDA labeling information — Xalkori. FDA website [online], (2011).

  7. 7

    Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. 8

    Camidge, D. R. et al. Progression-free survival (PFS) from a phase 1 study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 29, 2501 (2011).

    Article  Google Scholar 

  9. 9

    Shaw, A. T. et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12, 1004–1012 (2011).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10

    Choi, Y, L. et al. EML4–ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734–1739 (2010).

    CAS  Article  PubMed  Google Scholar 

Download references

Author information



Corresponding authors

Correspondence to Alice T. Shaw, Uma Yasothan or Peter Kirkpatrick.

Ethics declarations

Competing interests

Alice T. Shaw has been a consultant for Pfizer, Chugai and Ariad.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Shaw, A., Yasothan, U. & Kirkpatrick, P. Crizotinib. Nat Rev Drug Discov 10, 897–898 (2011).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing